en · de · es · fr · pt
assay-notes.peptides4088.com › Guide › Tesamorelin Identity And Structure — Practical Notes

Tesamorelin Identity And Structure — Practical Notes

By Editorial Desk · published 2026-02-17 · last reviewed 2026-03-17 · Guide

If you have been reading about 合成肽 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-03-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tesamorelin Identity And Structure

Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.

The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.

Identity and Development Background

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Tesamorelin at a glance

PropertyValueNotes
Chemical classSynthetic peptideGHRH analog family
Residue count44 amino acidsMatches human GHRH(1-44) backbone
N-terminal grouptrans-3-hexenoylMain structural difference from native hormone
AppearanceWhite to off-white powderLyophilized solid form
Solubility classFreely soluble in waterPeptide character; less soluble in organic solvents

Biological Role and Origin

Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.

The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.

Related pages on this site

Background and Clinical Profile

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

特沙莫瑞林历史与监管定位

特沙莫瑞林是一种合成肽,其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰,这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂,可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物,而非小分子化合物。

监管记录显示,特沙莫瑞林于 2010 年在美国首次获得批准,用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验,而非体重或瘦体重的普遍改善。后续出现了不同制剂版本,但其核心适应症保持一致。关于长期心血管结局和死亡率影响,现有证据仍不充分。

Molecular Background and Receptor Mechanism

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.

Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.

Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.

Background from the literature

in light of background scientific knowledge, the antecedent plausibility of TT is sufficiently low that any methodological flaw in a study will always provide a more plausible explanation for any positive findings. Emily Rosa, at nine years of age, conceived and executed a study on therapeutic touch. With the help of Quackwatch's Stephen Barrett and the assistance of her mother, Linda Rosa, and her step-father, Larry Sarner, Emily became the youngest researcher to have a paper accepted by the Journal of the American Medical Association (JAMA), which debunked the claim of therapeutic touch practitioners that they can reliably sense a "Human Energy Field." Twenty-one practitioners of therapeutic touch participated in her study. The practitioners sat on one side of a cardboard screen, while Emily sat on the other. The practitioners then placed their hands through holes in the screen. Emily flipped a coin to determine which of each practitioner's hands she would place hers over (approximately 4-5 inches above the subject's hand). The practitioners then were to say where her hand was by sensing her biofield. Although all of the participants had asserted that they would be able to do this, the actual results did not support therapeutic touch's fundamental claim. The practitioners had succeeded in locating Emily's hand 44% of the time, a rate lower than, though within the range of, mere chance. The JAMA editor George D.

By stimulating this angio- and vasculogenesis, CGB provides the placenta with a sufficient maternal blood supply, thus providing the embryo with the crucial nutrition it needs during its invasion of the uterine endometrium. As a more comprehensive overview: CGB promotes progesterone production by corpus luteal cells, promotes angiogenesis in uterine vasculature, promotes the fusion of cytotrophoblast cells and the subsequent differentiation to make syncytiotrophoblast cells, promotes the blockage of any immune or macrophage action by the maternal immune system on foreign invading placental cells, initiates proper and appropriate uterine growth parallel to fetal growth, suppresses any myometrial contractions during the course of pregnancy, stimulates growth and differentiation of the umbilical cord, prepares the endometrium for the approaching embryo implantation, acts on a receptor in mother's brain causing severe nausea and vomiting, and has also been shown to promote the growth of fetal organs during pregnancy.

The report concludes that the tactics of the Special Demonstration Squad were not justified, and that most groups infiltrated by its members posed no threat to national security. The report also finds that the SDS should have been disbanded early on. 30 June – Charlotte Dewar, chief executive of the Independent Press Standards Organisation, says the watchdog is considering the media coverage surrounding the death of Nicola Bulley, but has no current plans to launch an investigation.

Treatments are patient-specific and depend on the symptoms that present with the disorder, as well as the progression of the condition. Improvements to the patient's life may be accomplished through the management of symptoms or slowing of the rate of demyelination. Treatment can include medication, lifestyle changes (i.e. smoking cessation, increased rest, and dietary changes), counselling, relaxation, physical exercise, patient education, and in some cases, deep brain thalamic stimulation (to ameliorate tremors).

Sources: en.wikipedia.org

Further detail

Civil society in Pakistan is hierarchical, emphasising local cultural etiquette and traditional Islamic values. The primary family unit is the extended family, but there's a rising trend towards nuclear families due to socio-economic factors. Both men and women typically wear Shalwar Kameez; men also favour trousers, jeans, and shirts. The middle class has grown to about 35 million, with another 17 million in the upper and upper-middle classes, leading to a shift in power from rural landowners to urban elites. Festivals like Eid ul-Fitr, Eid ul-Azha, Ramadan, Christmas, Easter, Holi, and Diwali are primarily religious. Pakistan ranked 56th on the 2006 A.T. Kearney/FP Globalization Index due to increasing globalisation.

== Medical uses == It has been proven to be effective in various inflammatory skin diseases, e.g., seborrheic dermatitis, cutaneous lupus erythematosus, oral lichen planus, vitiligo, and psoriasis. Tacrolimus and pimecrolimus are both calcineurin inhibitors and function as immunosuppressants.

=== Early detection === From May to August 1939 the LZ130 Graf Zeppelin II made flights along Britain's North Sea coast to investigate the 100-metre-high radio towers that were being erected from Portsmouth to Scapa Flow. LZ130 performed a series of radiometric tests and took photographs. German sources report the 12 m Chain Home signals were detected and suspected to be radar; however, the chief investigator was not able to prove his suspicions. Other sources are said to report different results. During the Battle of France, the Germans observed 12 m pulse signals on the western front without being able to recognize their origin and purpose. In mid-June 1940, the Deutsche Versuchsanstalt für Luftfahrt (DVL, German Aeronautic Research Institute) set up a special group under the direction of Professor von Handel and found out that the signals originated from the installations on the coast of the English Channel. Their suspicions were finally proven in the aftermath of the Battle of Dunkirk, when the British were forced to abandon a mobile gun-laying radar (GL Mk. I) station in Normandy. Wolfgang Martini's team of specialists was able to determine the operation of the system. GL was a rather crude system of limited effectiveness, and this led the Germans to have a dim view of British radar systems. However, an effective system requires more than just the radar; plotting and reporting are equally important, and this part of the system was fully developed in Chain Home.

Locals are "Districts"; national convention meets quadrennially; headquarters in Pittsburgh; in 1979 had $120,000,000 in insurance; also sponsored outings, baseball games, etc. While originally for German men and women, by 1979 the Union was open to men and women of all ethnic backgrounds. In 1923 the Union had 54,000 members, 50,000 in 1965, and 37,000 in 1979. Improved Order, Knights of Pythias Independent Order of Red Men North American Swiss Alliance - Founded July 14, 1865, as the Grütli Bund der Vereinigten Staaten von Nord Amerika in Cincinnati. Became Nordamerikanishcher Schweizerbund in July 1911. National convention meets quadrennially, locals are called branches or lodges. Open to Swiss, Swiss descendants, or spouses of Swiss. Membership 2,000 in 1965, 4,000 in 1978 and 3,350 in 1994, about 10 to 15% are social, uninsured members. Periodical originally called Gruetlianer changed to Der Schweizer in 1911. Headquarters in Cleveland in 1979, but it was an "organization on wheels" moving to several places every few years in the late 19th century Schwarzer Ritter, Deutscher Orden - Claimed great antiquity, though in 1899 it was said to have been present in the United States for about 30 years. Active in New York, New Jersey, Pennsylvania, and the District of Columbia. Sons of Hermann United League of America Workmen's Benefit Fund - Founded as the Workmen's Sick and Death Benefit Fund in 1884, this organization was licensed to provide insurance in February 1899. The current name was adopted in 1939. Membership opened to non-Germans in 1976.

=== Metabolic/biochemical genetics === Metabolic (or biochemical) genetics involves the diagnosis and management of inborn errors of metabolism in which patients have enzymatic deficiencies that perturb biochemical pathways involved in metabolism of carbohydrates, amino acids, and lipids. Examples of metabolic disorders include galactosemia, glycogen storage disease, lysosomal storage disorders, metabolic acidosis, peroxisomal disorders, phenylketonuria, and urea cycle disorders.

Sources: en.wikipedia.org

Frequently asked questions

Is tesamorelin the same as growth hormone?

No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.

What does the trans-3-hexenoyl group do?

It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.

How long is the peptide chain?

The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.

What is tesamorelin made of?

It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.

Network